Literature DB >> 7005480

A pharmacologic and toxicological study of amygdalin.

C G Moertel, M M Ames, J S Kovach, T P Moyer, J R Rubin, J H Tinker.   

Abstract

Six patients with advanced cancer were treated with amygdalin (laetrile) at dosages similar to those employed by laetrile practitioners. Amygdalin given intravenously at 4.5 g/sq m/day was largely excreted unchanged in the urine and produced no clinical or laboratory evidence of toxic reaction. Amygdalin given orally at 0.5 g three times daily produced significant blood cyanide levels to 2.1 microgram/mL. No clinical or laboratory evidence of toxic reaction was seen in the six patients taking oral amygdalin at this dosage. One patient, however, challenged with a large intake of raw almonds, had transient symptoms of cyanide toxic reaction with escalating blood cyanide levels. This small study indicates that amygdalin in the doses employed produces few clinical side effects. A definite hazard of cyanide toxic reaction must be assumed, however, and possible long-term side effects remain unknown.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7005480

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  12 in total

Review 1.  Toxic phytochemicals and their potential risks for human cancer.

Authors:  Ann M Bode; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2014-10-27

Review 2.  Unproved dietary claims in the treatment of patients with cancer.

Authors:  M E Shils; M G Hermann
Journal:  Bull N Y Acad Med       Date:  1982-04

3.  Determination of amygdalin and its major metabolite prunasin in plasma and urine by high pressure liquid chromatography.

Authors:  A G Rauws; L G Gramberg; M Olling
Journal:  Pharm Weekbl Sci       Date:  1982-12-17

4.  Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells.

Authors:  Hae-Jeong Park; Seo-Hyun Yoon; Long-Shan Han; Long-Tai Zheng; Kyung-Hee Jung; Yoon-Kyung Uhm; Je-Hyun Lee; Ji-Seon Jeong; Woo-Sang Joo; Sung-Vin Yim; Joo-Ho Chung; Seon-Pyo Hong
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

5.  Pharmacology of amygdalin (laetrile) in cancer patients.

Authors:  M M Ames; T P Moyer; J S Kovach; C G Moertel; J Rubin
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  The pharmacokinetics of amygdalin.

Authors:  A G Rauws; M Olling; A Timmerman
Journal:  Arch Toxicol       Date:  1982-03       Impact factor: 5.153

7.  Amygdalin (Laetrile) and prunasin beta-glucosidases: distribution in germ-free rat and in human tumor tissue.

Authors:  J Newmark; R O Brady; P M Grimley; A E Gal; S G Waller; J R Thistlethwaite
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

Review 8.  Laetrile for cancer: a systematic review of the clinical evidence.

Authors:  Stefania Milazzo; Stephane Lejeune; Edzard Ernst
Journal:  Support Care Cancer       Date:  2006-11-15       Impact factor: 3.359

9.  Bioavailability of cyanide after consumption of a single meal of foods containing high levels of cyanogenic glycosides: a crossover study in humans.

Authors:  Klaus Abraham; Thorsten Buhrke; Alfonso Lampen
Journal:  Arch Toxicol       Date:  2015-02-24       Impact factor: 5.153

Review 10.  Laetrile treatment for cancer.

Authors:  Stefania Milazzo; Markus Horneber
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.